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 Aim: We evaluated the effect of Trx1 system on post-ischemic ventricular and 
mitochondrial dysfunction using transgenic mice overexpressing cardiac Trx1 and a dominant 
negative (DN-Trx1) mutant (C32S/C35S) of Trx1. Langendorff-perfused hearts were subjected to 15 
min of ischemia followed by 30 min of reperfusion (R). We measured left ventricular developed 
pressure (LVDP, mmHg), end diastolic pressure (LVEDP, mmHg) and t63 (relaxation index, msec). 
Mitochondrial respiration, SERCA2a, phospholamban (PLB), and p-PLB Thr 17 expression (Western 
blot) were also evaluated. Results: At 30 min of reperfusion Trx1 improved contractile state (LVDP: 
Trx1: 57.4±4.9 vs. Wt: 27.1±6.3 and DN-Trx1: 29.2±7.1, p <0.05); decreased myocardial stiffness 
(LVEDP: Wt: 24.5±4.8 vs. Trx1: 11.8±2.9, p<0.05) and improved the isovolumic relaxation (t63: Wt: 
63.3±3.2 vs. Trx1: 51.4±1.9, p<0.05). DN-Trx1 mice aggravated the myocardial stiffness and 
isovolumic relaxation. Only the expression of p-PLB Thr17 increased at 1.5 min R in Wt and DN-
Trx1 groups. At 30 min of reperfusion state 3 mitochondrial O2 consumption was impaired by 13% 
in Wt and by 33% in DN-Trx1. ADP/O ratios for Wt and DN-Trx1 decrease 25% and 28% 
respectively; whereas the Trx1 does not change after I/R. Interestingly, baseline values of complex 
I activity were increased in Trx1 mice, they resulted 24% and 47% higher than in Wt and DN-Trx1 
mice, respectively (p<0.01). Innovation and Conclusion: These results strongly suggest that Trx1 
ameliorates the myocardial effects of I/R by improving the free radical mediated damage in 
cardiac and mitochondrial function, opening the possibility of new therapeutic strategies in 

































































































































































































 The stunned myocardium is a reversible post-ischemic ventricular dysfunction that occurs 
after a short period of ischemia followed by reperfusion. It is characterized by a decrease in the 
contractile state accompanied by an alteration of the diastolic function (5). It is noteworthy that 
this pathophysiological entity is frequently present in patients undergoing reperfusion therapies 
such as treatment with thrombolytics, angioplasty, and coronary by-pass surgery (6). 
 It is known that stunned myocardium involves an impairment of the calcium (Ca2+) 
homeostasis, accompanied by an increase of oxidative stress and damage (20, 23, 49). Several 
authors have pointed out that during reperfusion there is a notable increase in the mitochondrial 
superoxide radical anion (O2
-) and hydrogen peroxide (H2O2) production which leads to cell 
damage (7, 23, 48). This mitochondrial production of O2
- and H2O2 occurs both in physiological (12, 
9) as in pathophysiological conditions, such as ischemia and reperfusion injury (I/R) (30, 41, 48).  
 We have previously demonstrated, in isolated rabbit hearts, that stunned myocardium is 
associated to a mitochondrial dysfunction called “complex I syndrome”, with decrease in tissue 
and mitochondrial O2 consumption and increase of the H2O2 and peroxynitrite (ONOO
-) production 
(48). Accordingly, Demaison et al. noted that mitochondrial dysfunction is part of the deleterious 
mechanism of stunned myocardium (15, 16). Recently, Luo et al. (31) also demonstrated that 
some protective interventions, such as ischemic postconditioning, are capable of reverting post-
ischemic ventricular dysfunction due to an improvement of mitochondrial function through the 
activation of the reperfusion injury salvage kinase (RISK) pathway. These studies show a 
relationship among the ventricular and mitochondrial function, and the proteins involved in the 
protective mechanisms. Due to the aforementioned reference to oxidative stress in stunned 
myocardium, it is important to study the role of antioxidant systems on this pathophysiological 
entity. In this sense, thioredoxin (Trx) takes part in one of the most important cellular antioxidant 
systems known to date (33). Particularly, Trx1 exerts a protective effect against I/R injury, reducing 
the infarct size (1, 56). However, there is no enough experimental evidence, at least to our 
knowledge, that this cardioprotection is extended to post-ischemic ventricular dysfunction. 
Yoshioka et al. reported that a deficiency in the thioredoxin interacting protein (TXNIP) improves 
the recovery of mitochondrial and ventricular function of the stunned myocardium (54), but they 
did not show a specific effect of Trx1 on ventricular function. Furthermore, they used a transgenic 
model, with a thioredoxin interacting protein (TXNIP) deficiency that has normal myocardial Trx1 
activity and abnormal mitochondria morphology (55, 56). Due to these reasons, the aim of this 
























































































































































































work was to study for the first time the role of Trx1 on post-ischemic ventricular dysfunction. We 
evaluated the behavior of the systolic and diastolic ventricular function during stunned 
myocardium in transgenic mice with cardiac-specific overexpression of Trx1 and a dominant 
negative mutant (C32S/C35S) of Trx1 (DN-Trx1) mice, in which the activity of endogenous Trx1 is 
diminished.  Both components of diastolic function, isovolumic relaxation and myocardial stiffness 
were evaluated. An additional goal of this study was to evaluate whether stunned myocardium 
also induces changes in the mitochondrial function, in the sarco/endoplasmic reticulum Ca2+-










































































































































































































 Figure 1 shows the behavior of ventricular function in Wt and both transgenic mice. The 
left ventricular developed pressure (LVDP, Panel A) and the first derivative of LV pressure 
(LV+dP/dtmax, Panel B), represent the contractile state. No differences were observed in the LVDP 
at baseline conditions among the groups. However, a significant decrease of the LVDP was 
observed at 30 min of reperfusion in Wt and DN-Trx1 mice compared to Trx1 mice (Wt: 27.1±6.3; 
DN-Trx1: 29.2±7.1 mmHg vs. Trx1: 57.4±4.9; p<0.05). Thus, Trx1 mice showed a significant 
improvement in the recovery of the contractile state at 30 min of reperfusion, and this beneficial 
effect was abolished in the DN-Trx1 mice. The LV+dP/dtmax had a similar behavior to the LVDP 
(Panel B). The left ventricular end diastolic pressure (LVEDP, Panel C) reflected a significant 
increase of myocardial stiffness at 30 min of reperfusion in the Wt group (24.5±4.8 mmHg). This 
deleterious effect was exacerbated in DN-Trx1 mice (37.7±5.5 mmHg, p≤0.05 vs. Wt y Trx1), and 
clearly attenuated in the Trx1 mice (11.8±2.9 mmHg; p≤0.05 vs. Wt y DN-Trx1). In regards to t63 
(Panel D), a decrease in relaxation rate at the onset of reperfusion (1.5 min) was observed in the 
Wt and DN-Trx1 groups (63.3±3.2 y 65.4±5.2 msec). These antirelaxant effects were not observed 
in Trx1 mice (Trx1: 51.4±1.9 msec, p<0.05 vs. Wt and DN-Trx1). At the end of reperfusion (30 min) 
both the Wt and the Trx1 groups returned to t63 similar to the pre-ischemic values (Wt: 52.1±2.1 
and Trx1: 47.5±2.5 msec). However, in the DN-Trx1 group, the decrease in relaxation rate was 
exacerbated compared to the Wt and the Trx1 mice (78.2±9.8 msec, p<0.05 vs. Wt and Trx1).  
 Figure 2 shows the expression of PLB and SERCA2a proteins, both associated with 
myocardial relaxation. Total PLB and SERCA2a did not show significant changes, neither among 
their baseline values, nor after early reperfusion (1.5 min) in the different groups studied.  
Phosphorylation of PLB at Thr17 residue, increased in Wt and DN-Trx1 group at reperfusion 
compared with pre-ischemic values (Wt: 1.76±0.22; DN-Trx1: 1.35±0.12, p<0.05 vs. respective 
baseline values, Panels A, E). In the Trx1 mice, an increase in the Thr17 phosphorylation 
(1.38±0.17, p<0.05 vs. Wt and DN-Trx1) was already observed in baseline conditions. However, no 
changes were observed during reperfusion (Panel C).     
 Heart mitochondrial function after I/R was evaluated by the determination of state 3 
(active) and state 4 (resting) rates of O2 consumption (Table 1, Figure 3). State 3 O2 uptake 
supported by malate-glutamate was significantly impaired after I/R in Wt mice (13% decrease) and 
in DN-Trx1 mice (33% decrease, p<0.001). On the contrary, mitochondria from Trx1 mice did not 
show a significant change in active respiration after I/R. After I/R, Trx1 mice showed state 3 
























































































































































































respiration values significantly higher than Wt (24%, p<0.05) and DN-Trx1 mice (47%, p<0.001). 
Concerning to state 4 respiration, the O2 consumption rate without ADP, it remained almost 
unchanged after I/R in Wt, Trx1, and DN-Trx1 mice. Interestingly, Trx1 mice showed increased 
state 4 values after I/R. Considering the respiratory control (RC) values, using the ratio between 
state 3/state 4 respiration, after I/R, a slight decrease (16%) in the Wt and Trx1 groups and a 
moderate decrease (31%) in the DN-Trx1 mice, were detected. The ADP/O (Figure 4) ratio is an 
indicator of the efficiency of oxidative phosphorylation, i.e. the ATP production coupled to O2 
consumption. The I/R process produced a significant decrease in ADP/O ratios for Wt and DN-Trx1, 
25% and 28% respectively; whereas the Trx1 mice showed unchanged ADP/O values. The effects 
observed in state 3 and in state 4 respirations, RC, and ADP/O ratios in the comparison between 
Wt, Trx1 mice, is interpreted as evidence of an effective protection of Trx1 in the oxidative 
damage after mouse heart I/R. Table 2 shows mitochondrial O2 consumption in the presence of 
oligomycin, an inhibitor of ATP synthesis. No significant changes between baseline conditions and 
after I/R in Wt and Trx1 groups were observed, but only DN-Trx1 group I/R produced a significant 
decrease.  Although, Trx1 mice showed an increased in state 4o values after I/R compared with Wt 
and DN-Trx1 groups (Table 2). In presence of the uncoupler carbonylcyanide-3-
chlorophenylhydrazone (m-CCCP), we observed a similar behavior regarding mitochondrial O2 
consumption in malate-glutamate state. After I/R, a non significant decrease in state 3u values in 
the Wt in relation to their baseline value (14%), and a significant decrease in the DN-Trx1 group 
(27%, p<0.05), were observed. In the Trx1 there were no differences between baseline conditions 
and after I/R.  After I/R, Trx1 mice showed state 3u respiration values significantly higher than Wt 
(23%, p<0.05) and DN-Trx1 mice (29%, p<0.01).  The respiratory impairment of mouse left 
ventricle mitochondria was further investigated by assaying the activity of mitochondrial 
respiratory complexes (Figure 5). Complex I, which has been reported as selectively damaged after 
I/R in rabbits (48), showed a non-significant decrease of 14% in the Wt group, 9 % in DN-Trx1 mice, 
and 10% in the Trx1 mice (Panel A). Interestingly, baseline values of complex I activity were 
increased in Trx1 mice. Their results were significantly higher than in Wt (27% <0.05) and in DN-
Trx1 (47%, p<0.01) mice. Complex IV activities slightly decrease by I/R in Wt and Trx1 mice. 
However, DN-Trx1 group showed an inhibition of 20% after I/R process (Panel B). 
 The emission of H2O2 was assessed in energized isolated mitochondria using complex I 
substrates to establish state 4 (Figure 6). The rates obtained for the Wt and Trx1 mice were 
similar, whereas baseline values for DN-Trx1 were higher than for the other two groups. After I/R, 
























































































































































































an increase was observed for Wt (29%) and DN-Trx1 mice (47%), meanwhile in Trx1 mice a slight 
but non-significant H2O2 formation increase (14%) was detected.  
 Finally, we also measured mitochondrial aconitase activity in order to assess the 
production of oxidant and nitrating species in vivo (Table 3). No significant changes in activity of 
this enzyme were observed after stunning, i.e. I/R in Wt, Trx1 and DN-Trx1 groups. 

























































































































































































 In the present study we have demonstrated that the overexpression of Trx1 in transgenic 
mice attenuates systolic and diastolic post-ischemic ventricular dysfunction (stunned 
myocardium), considering both isovolumic relaxation and myocardial stiffness. Consistent with 
these results, we observed that the beneficial effect was abolished in DN-Trx1 transgenic mice, in 
which the activity of endogenous Trx1 is reduced (50). Even more, in these mice was observed an 
exacerbation in myocardial stiffness and isovolumic relaxation alterations, compared to the Wt 
mice at the end of reperfusion.  At least to our knowledge, only Yoshioka et al. (54) studied the 
effects of the Trx1 system in a model of pure myocardial stunning, in absence of necrosis. 
However, this study has profound differences with ours. First, the aforementioned authors used a 
transgenic model with a thioredoxin interacting protein (TXNIP) deficiency, but in a previous work 
of the same authors (55) they were unable to demonstrate that TXNIP KO increases Trx1 activity. 
For these reason, TXNIP KO mice are not comparable to our experimental model, where there is a 
clear increase of Trx1 expression and activity; second, TXNIP KO mice have abnormal mitochondria 
in the heart, which cannot be explained by Trx1 since transgenic mice have normal mitochondria 
(55). Finally, as it was previously mentioned, these authors only evaluated the systolic function. 
Taken together, we can conclude that our study is the first to show a direct effect of cytosolic Trx1 
on systolic and diastolic ventricular function, the signaling pathway involved in relaxation 
impairment and their relationship to mitochondrial function.   
  The beneficial effects on the ventricular diastolic function were accompanied by 
normalization in the PLB phosphorylation at Thr17, which was increased in the Wt and the DN-
Trx1 mice at the onset of reperfusion. Moreover, mitochondrial function was altered in Wt mice 
during late reperfusion, shown by a decrease in the mitochondrial O2 consumption in state 3, 
accompanied by a slightly drop of complex I activity, after I/R. In DN-Trx1 mice, this alteration after 
I/R was exacerbated in both O2 consumption and complex I activity, in accordance to the 
exacerbation of diastolic dysfunction at 30 min of reperfusion. Conversely, overexpression of Trx1 
was associated to a slighter drop in the complex I activity without changes in O2 consumption in 
mice hearts subjected to a stunning protocol. Thus, we showed that Trx1 overexpression exerts 
cardioprotective effects on the stunned myocardium including a modification in the 
phosphorylation of PLB and an improvement in the mitochondrial function.   
 In this study, the behavior of the ventricular function at the onset of reperfusion was 
accompanied by changes in the phosphorylation of the PLB in the Thr17 residue, without changes 
























































































































































































in the SERCA2a and total PLB expression. First in relation to TG overexpressing Trx1 and then in Wt 
and DN-Trx1 mice, our data show that in Trx1 mice, the hearts have a higher p-PLB Thr17 
phosphorylation in comparison to Wt and DN-Trx1 at baseline condition. This PLB behavior before 
a certain intervention, in our case ischemia, was also shown by Catalucci et al (13). These authors, 
and in concordance with our findings, demonstrated that at baseline conditions, a higher p-PLB 
Thr17 phosphorylation is accompanied by a greater Ca2+ reuptake by the sarcoplasmic reticulum 
(13), but in their case they used a transgenic model with Akt overexpression. Therefore maybe 
that our mice, which at baseline conditions have a higher PLB phosphorylation, avoid at least 
partially, a Ca2+ overload during reperfusion when subjected to a protocol of I/R. This may justify 
the lack of isovolumic relaxation impairment at the onset of reperfusion. Second, the behavior of 
p-PLB Thr17 in Wt and DN-Trx1 after ischemia is different. It was observed that unlike TG Trx1, 
there was an increase in p-PLB Thr17 in Wt and DN-Trx1 at the onset of reperfusion (1.5 min). 
These changes were accompanied by a slowing of isovolumic relaxation rate. This increase in early 
reperfusion phosphorylation with a deleterious functional repercussion are consistent with those 
who showed that increases in PLB phosphorylation (Thr17) at the onset of reperfusion to try to 
correct the Ca2+ homeostasis alteration that occurs, and normalizing relaxation in the last stages of 
reperfusion (36, 37, 44). It has been widely shown that an increase in both, the expression and 
activity of SERCA, could avoid the Ca++ overload that occurs during reperfusion after I/R episode 
(27, 40, 45, 46). Gou et al. showed that I/R induced endoplasmic reticulum stress, SERCA 
dysfunction and subsequent impairment in ventricular function (22). Moreover, Kuster et al. (29) 
demonstrated in cardiomyocytes that exposure to H2O2 100 mM produces a systolic dysfunction 
characterized by reduced contractility and inhibition of SERCA. Taken together, and given that in 
our Trx1 mice we have a better redox balance, we could assume an improvement in SERCA 
function and as a consequence decreased Ca2+ overload after I/R. Due to the aforementioned, our 
data suggest that an increase of the cell antioxidant defenses in baseline conditions would avoid 
the relaxation impairment after ischemia, in early reperfusion in hearts subjected to a protocol of 
myocardial stunning. This increase in antioxidant defenses would be given in our experimental 
model by Trx1 overexpression  
 The mitochondrial dysfunction observed in this study, also termed “complex I syndrome”, 
is characterized by a reduction of O2 uptake, malate-glutamate mitochondrial respiration, and 
complex I activity. It was also observed an augmentation of protein nitration and oxidations 
products, and increased O2
- and H2O2 production rates (48). Previous reports demonstrated that 
























































































































































































complex I is the major target of mitochondrial damage after I/R injury (21, 48). In this study, we 
observed a slightly drop of 18% in complex I activity at the end of reperfusion in Wt mice. In this 
condition, a failure in myocardial function is evidenced, in the contractile phase, as expected, but 
also in both components of the diastolic phase:  isovolumic relaxation, and myocardial stiffness.  In 
parallel, there is a mitochondrial dysfunction, with decreased mitochondrial O2 consumption, 
ADP/O ratios and mitochondrial complexes activity. The results reported here describing 
myocardial and mitochondrial dysfunction in mouse stunned myocardium are similar to the ones 
previously reported in rabbit stunned hearts (48). This protective role of Trx1 also supports the 
concept that the mechanism of I/R involves an increased rate of free-radical mediated reactions 
which lead to a condition of oxidative stress. In the reperfusion, there is an abrupt change in 
cellular O2 levels and a fully reduced mitochondrial respiratory; these facts results in a primary 
burst of O2
- generation (4, 48, 51). This primary product (O2
-) is rapidly dismutated to H2O2 which in 
turn generates hydroxyl radical (HO·). This last specie is capable of initiating free radical-mediated 
reactions, called lipoperoxidation, in which organic hydroperoxides (ROOH) are produced (32). The 
first part of the oxidative stress description occurring after I/R protocol is explained by the 
overproduction of H2O2 and ROOH, which are relatively stable products (32). The second part 
implies the oxidation of thiol groups with regulatory and signaling functions (39). The properties of 
the thioredoxin system that reduces the production of H2O2, ROOH, and disulfide groups at fast 
rates clearly explain the biochemical mechanism of the antioxidant effect (39).  Regarding complex 
I we also measured mitochondria-specific markers of oxidative stress such as aconitase activity, 
trying to provide strong support for in vivo mitochondrial ROS production. Unfortunately, in our 
model of short ischemia (myocardial stunning) no changes were observed regarding complex I 
activity and aconitase. This behavior could be related to the fact that values are in the nanomolar 
range, and it is unlikely that aconitase would be damaged and inactivated significantly in this short 
ischemia-reperfusion model of myocardial stunning. This behavior in aconitase activity was also 
shown by other authors (3, 26). In this sense, Balteu et al. (3) using a rat model subjected to 30 
min of ischemia and 60 min of reperfusion showed an reversible inactivation of aconitase activity. 
They demonstrated that this activity decreased 65% compared with a control group at 5 min of 
reperfusion, but at 15 min of reperfusion these values reached similar to pre-ischemic values. In a 
similar manner, Koga et al. (26), although using 15 min of ischemia, the same as our protocol, only 
observed changes in aconitase activity at 5 min of reperfusion. Taking this information as a whole, 
























































































































































































it may be that changes in this enzyme activity occur in early reperfusion. This may explain why 
when we measure it at 30 min of reperfusion; we cannot evidence a decrease in its activity.   
 An interesting finding of this study was that mice overexpressing Trx1 show an increased 
(24%) activity of mitochondrial complex I in baseline conditions, meanwhile in DN-Trx1 animals 
show a decreased (16%) in this activity. The mechanism underlying these observations may 
comprise protein S-glutathionylation, the reversible conjugation of GSH to cysteines within a 
protein. S-glutathionylation has been shown to play an important role in modulating mitochondrial 
function and morphology (17, 24, 34). Have been shown that several subunits of the Complex I are 
crucial for regulation by S-glutathionylation (14, 25, 35). This covalent modification of Complex I 
lead to the inactivation of this protein. Moreover, Complex I from heart and other tissues has been 
shown to be susceptible to regulation by glutathionylation reactions (25, 42). Has also been shown 
that subunit Ndufa11 suffers S-glutathionylation in isolated perfused heart mice model subjected 
to I/R (28). The increase in S-glutathionylation in GSH depleted conditions, i.e.  DN-Trx1 mice might 
be surprising at first. However, given that GSH is a cofactor for GSH reductase-catalyzed 
deglutathionylation, the reduction of the levels of GSH could limit GSH reductase activity, and 
therefore enhance S-glutathionylation.  During oxidative stress, cysteines are among the most 
vulnerable with regard to oxidative modifications. GSH, an antioxidant component, is present at 
millimolar concentrations in the cells (1–10 mM), and the conjugation of GSH to oxidized cysteines 
acts as a cytoprotective mechanism to prevent oxidation. Of note, S-glutathionylation occurs not 
only in response to overt oxidative injury but also in pathophysiological states, and in settings 
where ratios of GSH to oxidized GSH (GSSG) are low (i.e. 100:1 vs. 3:1).  
 It has been shown that mitochondrial thiols keep the steady-state levels of mitochondrial 
H2O2 , cellular redox homeostasis, and cytosolic redox-sensitive signaling modulation; changes in 
these thiols could affect transcription, growth, and finally modulate the behavior in cell survival 
pathways. Mitochondria is able to generate second messengers (redox: H2O2 and NO; energy: ATP) 
which are involved in the regulation of redox/energy sensitive cell signaling pathways, this way 
could generate physiological actions between mitochondria and other proteins (52, 53). 
Contrasting, several molecules can translocate into the mitochondria and performed redox 
changes in others organelles. The redox environment could be regulated by communication 
between mitochondria and other cell components (52). Thus, changes in the redox balance in 
cytosol, e.g. Trx1 overexpression, could produces regulatory changes in mitochondria that were 
























































































































































































evidenced, in this work, through state 3 oxygen consumption (active respiration), ADP/O ratio, 
H2O2 production, and complex I activity. 
 In summary, we have demonstrated that Trx1 overexpression has a clear protective effect 
on the stunned myocardium, not only on the contractile state, but also on the two diastolic 
components: isovolumic relaxation and myocardial stiffness. Furthermore, the improvement in 
isovolumic relaxation rate reflected a decrease in the p-PLB; and the attenuation of myocardial 
stiffness involved a clear improvement of mitochondrial dysfunction, evidenced by almost 
unchanged rates of O2 consumption, ATP production and complexes activity. 
 
INNOVATION 
 While thioredoxin system and particularly Trx1 exerts a protective effect against injury by 
I/R, reducing the infarct size; there is no enough experimental evidence that this cardioprotection 
is extended to myocardial stunning. Our novel results strongly suggest that Trx1 ameliorates 
systolic and diastolic dysfunction of myocardial stunning, including isovolumic relaxation and 
myocardial stiffness, by improving the free radical mediated damage in ventricular and 
mitochondrial function. The description of these new regulatory mechanisms in myocardial 
stunning opens the possibility to new therapeutic strategies in the ischemia/reperfusion injury. 
 
























































































































































































MATERIALS AND METHODS 
Animal care 
 The experimental protocol was approved by the Animal Care and Research Committee of 
the University of Buenos Aires (UBA # 0037016/2010). Mice were housed in ventilated cages with 
a 12hs light/dark cycle and controlled temperature (20–22°C), and fed with normal chow and 
water ad libitum. 
Transgenic mice 
 We have used the transgenic mice from the same colonies of Prof. Junichi Sadoshima, who 
generously donated these mice to us. Two transgenic mice models were used: 1) transgenic mice 
with cardiac-specific overexpression of Trx1 (Trx1) generated on an FVB background using the α-
myosin heavy chain promoter to achieve cardiac-specific expression (2, 50), and 2) DN-Trx1 was 
generated by mutation of 32Cys and 35Cys of hTrx1 to Ser using QuikChange (Stratagene, La Jolla, 
California, USA). This redox inactive mutant of Trx1 works as a dominant negative for endogenous 
Trx1 in mice hearts (50).Wild type mice (Wt) were also used as control group. 
Isolated mice hearts 
 The hearts of three month-old male mice weighting 24.2 ± 1.5 g were used. Mice were 
anesthetized by an intraperitoneal injection of sodium pentobarbital (150 mg/kg) and sodium 
heparin (500 IU/kg, bolus i.p). After anesthesia, hearts were excised and the aorta was 
immediately cannulated with a 21 gauge cannula. Hearts were rapidly excised and perfused 
according to the Langendorff technique. We performed 20 min of stabilization, 15 min of global 
ischemia, and 30 min of reperfusion. Hearts were perfused with Krebs bicarbonate buffer 
containing (in mM): NaCl 118.5, KCl 4.7, NaHCO3 24.8, KH2PO4 1.2, Mg SO4 1.2, CaCl2 1.5 and 
glucose 10, bubbled with 95% O2 and 5% CO2 (pH = 7.40) at 37°C  as previously described (43). Two 
electrodes were sutured and connected to a pacemaker to produce a constant heart rate of 472±3 
beats/min. The coronary perfusion pressure (CPP) was monitored through a pressure transducer 
connected to the perfusion line. Hearts were perfused at a constant flow of 4.01±0.20 ml/min, 
which was adjusted to obtain a CPP of 73±3 mmHg in the initial stabilization period and 
maintained constant throughout the experiment. Left ventricular developed pressure (LVDP) and 
the maximal rate of rise of left ventricular pressure (LV+dP/dtmax) were determined as contractile 
























































































































































































state indexes. Isovolumic relaxation rate was analyzed using t63, defined as the time required for 
the left ventricular pressure to fall to 63%. Left ventricular end diastolic pressure (LVEDP), a 
myocardial stiffness index, was also measured.  
Mitochondrial isolation and mitochondrial membrane preparation 
Heart mitochondria were obtained from mouse heart homogenates by differential 
centrifugation in a refrigerated centrifuge (Sorvall-Instruments-Du Pont, model RC5S, 
Buckinghamshire, England). Left ventricles were excised, washed, and minced in ice-cold STE 
buffer containing 250 mM sucrose, 10 mM Tris-HCl and 2 mM EGTA, pH 7.4. A brief digestion was 
performed in STE medium supplemented with 0.5% (w/v) fatty acid-free BSA, 5 mM MgCl2, 1 mM 
ATP and 2.5 UI/mL type XXIV bacterial proteinase. After 4 min at 4°C, hearts were homogenized 
with a small Potter-Elvejhem glass-Teflon homogenizer after the addition of 5 volumes of STE 
buffer, and centrifuged at 8000 g for 10 min. The obtained pellet was resuspended in ice-cold STE 
buffer and centrifuged at 700 g for 10 min. The pellet was discarded and mitochondria were 
precipitated by two 10 min-centrifugations at 8000 g. Finally, mitochondria were resuspended at 
about 20 mg protein/ml in STE buffer. The whole procedure was carried out at 0–4 C (38). It is to 
be remarked that this procedure allowed the isolation of 1.5-2.1 mg of heart mitochondrial 
protein from a single mouse.  Mitochondrial membranes were obtained by two cycles of freezing 
and thawing of the mitochondrial preparation, followed by homogenization by passage through a 
29 G hypodermic needle (11). Protein concentration was measured by the Folin reagent using BSA 
as standard.    
Mitochondrial O2 consumption 
Mitochondrial O2 uptake was determined polarographically with a Clark-type electrode 
(Oxytherm, Hansatech Instruments Ltd, Norfolk, England) in a 1.0-ml chamber at 30°C in an air-
saturated reaction medium ([O2]  = 220 μM).  Heart mitochondria were suspended, at 0.2-0.3 mg 
protein/mL, in a respiration buffer consisting of 120 mM KCl, 5 mM KH2PO4, 1 mM EGTA, 20 mM 
HEPES and 1 mg/mL fatty acid-free BSA, pH 7.40, 2 mM malate and 5 mM glutamate as substrates 
without (state 4) or with the addition of 0.5 mM ADP (state 3) (10). Respiration is expressed in ng-
at O/min × mg protein. Respiratory control was calculated as the ratio of state 3/state 4 
respiration rates. Oligomicin (0.2 µM) and carbonyl cyanide m-chlorophenylhydrazone (m-CPPP, 1 
























































































































































































µM) were used to set state 4o and state 3u. These measurements were performed at baseline 
conditions (0/0) and after 30 min of reperfusion (15/30).  
Activities of mitochondrial respiratory complexes 
The enzymatic activities of mitochondrial complexes I and IV were determined 
spectrophotometrically (Beckman DU 7400 spectrophotometer) at the a-band of cytochrome c 
(550 nm, E = 19 mM-1 cm-1) at 30°C. With mitochondrial membranes suspended in 100 mM 
KH2PO4/K2HPO4, pH 7.40, complex I activity was determined as NADH-cytochrome c reductase. 
Mitochondrial membranes were added with 0.20 mM NADH as substrate, 25 M cytochrome c3+ 
and 0.5 mM KCN. Enzymatic activities are expressed as nmol cytochrome c2+/min × mg protein. 
Complex IV (cytochrome oxidase) was determined in the same buffer supplemented with 50 M 
cytochrome c2+. Reduced cytochrome c was prepared by reduction of cytochrome c3+ with 
Na2S2O4, followed by Sephadex G-25 chromatography. The rate of cytochrome c
2+ oxidation was 
calculated as the pseudo-first order reaction constant k´/mg protein. These measurements were 
performed at baseline conditions (0/0, n=4 per group) and at 30 min of reperfusion (15/30, n=5 
per group).   
Western blots  
Hearts samples (n=6 per group) were homogenized at 0C for 2 min in 20 mM Tris, 30 mM 
NaCl, 0.1% SDS, 1% Triton, 0.2 mM DTT, pH 7.40, protease and phosphatase inhibitors at a ratio of 
330 μL every 100 mg of heart using a PRO 200 Scientific homogenizer. Homogenates were 
centrifuged at 800 g for 10 min at 0-4C. The supernatant protein was quantified with the 
Bradford reagent. Homogenate proteins, 50 µg of each sample, were separated by electrophoresis 
in 16% Tricine-SDS-PAGE gels and transferred to a PVDF membrane (Thermo Fisher Scientific Inc., 
Waltham, MA USA), and blocked with 5% BSA for 2 hours at room temperature. Subsequently, the 
samples were incubated with anti PLB, (1:5000) (Badrilla Ltd., West Yorkshire, United Kingdom) 
and phosphorylated PLB Threonine 17 residue (Thr 17; 1: 3000) (Badrilla); and finally, anti SERCA2a  
(Thermo Scientific) (1:1000) antibodies overnight at 4C with agitation. Later, the samples were 
incubated with anti-rabbit secondary antibody conjugated with horseradish peroxidase (HRP, 
1:20000) (EMD Millipore Corporation, Darmstadt, Germany), for 1 hour at room temperature. The 
membrane was developed with photographic plates (Eastman Kodak Company, Rochester, New 
York, United States) and Super Signal West picochemiluminescent substrate (Thermo Scientific). 
























































































































































































These proteins expressions were quantified by densitometry with Image Gauge 4.0 software 
(FUJIFILM Holdings Corporation, Tokio, Japan), and data were expressed as relative to GADPH 
expression (1:3000) (Cell Signaling Technology Inc., Danvers, United States). These measurements 
were performed at baseline conditions (0/0) and at 1.5 min of reperfusion (15/1.5).   
Hydrogen peroxide production 
 Hydrogen peroxide (H2O2) production was determined fluorometrically at 365-450 nm 
(Hitachi F-3010 spectrofluorometer) using the scopoletin-horseradish peroxidase assay (8), at 30 
°C. The reaction medium consisted of mannitol 230 mM, sucrose 70 mM, 30 mM Tris-HCl pH 7.40, 
7 mM succinate, 0.6 µM Cu,Zn-SOD, 1 µM HRP, 1 µM scopoletin, and heart coupled mitochondria 
(0.02-0.05 mg protein/ml), without or with the addition of 10 µM catalase. A calibration curve was 
performed using H2O2 (0.05-0.35 µM) to express the fluorescence changes as nmol H2O2/min . mg 
protein. Only the fluorescence change inhibited by catalase addition was considered to calculate 
H2O2 production. 
Aconitase activity 
 Aconitase activity was measured spectrophotometrically in mitochondrial samples (19). 
Freshly isolated mitochondria samples were sonicated (4 bursts of 30 s ON and 60 s OFF) followed 
by centrifugation at 8250 g for 10 min at 4 °C. Specific activity of the mitochondrial aconitase 
present in the supernatant was measured by monitoring the conversion of sodium citrate to cis-
aconitase at 37 °C (240 nm,  = 3.6 mM−1cm−1) (18, 47).  The reaction medium contains 100 mM 
Tris-HCl buffer (pH 7.4), 1 mM sodium citrate, 0.05 -0.08 mg mitochondrial protein/ml.  The 
activity is expressed as nmol/min × mg protein. These measurements were performed at basal 
conditions (0/0) and at 30 min of reperfusion (15/30).   
Statistics 
Results are expressed as means ± SEM. Ventricular function and western blot:  Inter-group 
comparisons were performed using analysis of variance and then the Bonferroni test for multiple 
comparisons. p<0.05 was considered statistically significant. Mitochondrial function: Student-
Newman-Keuls test was used to analyze the significance of differences. Figures and tables include 
the significance in the differences within groups (i.e. 15/30 vs. 0/0) and among groups in the same 
condition (i.e. 0/0 or 15/30).   
























































































































































































LIST OF ABBREVIATIONS 
CPP: Coronary perfusion pressure. 
DN-Trx1: Transgenic mice with cardiac-specific overexpression of dominant negative for 
endogenous Trx1. 
H2O2: Hydrogen peroxide 
I/R: Ischemia/reperfusion. 
I: Ischemia. 
LV: Left ventricular. 
LV+dP/dtmax: Maximal rate of rise of left ventricular pressure. 
LVDP: Left ventricular developed pressure. 
LVEDP: Left ventricular end diastolic pressure. 
p- PLB: Phospholamban phosphorylation. 
PLB: Phospholamban protein. 
R: Reperfusion. 
RC: Respiratory control. 
SERCA2a: Sarcoplasmic reticulum Ca2+- ATPasa. 
t63: Time required for the left ventricular pressure to fall to 63% (relaxation index). 
Trx: Thioredoxin. 
Trx1: Thioredoxin-1; transgenic mice with cardiac-specific overexpression of Trx1  
TXNIP: Thioredoxin interacting protein. 
Wt: Wild-type mice. 
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Figure 1. Ventricular function. Panels A and B show the myocardial contractility indexes, the left 
ventricular developed pressure (LVDP, mmHg) and  the maximal rate of rise of left ventricular 
pressure +dP/dtmax (mmHg/sec) respectively. An improvement of the contractile state in Trx1 
(n=11) in relation to Wt (Wild type, n= 12) and DN-Trx1 (dominant negative for Trx1, n= 9) was 
observed. Panel C shows the left ventricular end diastolic pressure (LVEDP, mmHg), an index of 
myocardial stiffness. LVEDP increase in Wt and DN-Trx1 during reperfusion, but is attenuated in 
Trx1 mice. Panel D shows t63, an index of isovolumic relaxation. t63 shows a slow relaxation rate 
in Wt and DN-Trx1, while in Trx1 group this impairment is not observed. *p≤0.05 Wt and DN-Trx1 
vs. Trx1. #p≤0.05 vs. Trx1. 
 


























































































































































































Figure 2. Western blots. Panels A, C, and E show the values of phosphorylated phospholamban in 
Threonine 17 residue (p-PLBThr17) in the three studied groups. At 1.5 min of reperfusion there is 
an increase in the p-PLBThr17 phosphorylation both in the Wt group (Panel A) and in the DN-Trx1 
(Panel E). However this is not observed in Trx1 group (Panel C), which maintains the same value as 
in normoxic conditions (Nx). Panels B, D, and F show the SERCA2a values for all groups, which do 
not present variations in the normoxic conditions and neither at 1.5 min of reperfusion among the 
groups. Panel G shows the representative bands of pPLBThr17, total PLB, SERCA2a, and GADPH for 
all groups, the last one being used as loading control. n=6 per group *p≤0.05 vs. Nx, respectively.    
   


























































































































































































Figure 3.  Representative traces obtained during the polarographic measurement of mitochondrial 
O2 consumption: A: Wild type (Wt) in baseline conditions; B: Wt after 15 min of ischemia and 30 
min of reperfusion (I/R); C: Trx1 I/R; D: DN-Trx1 I/R.  Arrows correspond to the addition of 0.25 mg 
mitochondria/ml, 2 mM malate + 5 mM glutamate (state 4), 0.5 mM ADP (state 3), 0.2 μM 
oligomycin (state 4o) and a μM m-CCCP (state 3u).  
 


























































































































































































Figure 4.  Respiratory control values. The ischemia/reperfusion ( I/R) process produced decreased 
ADP/O ratios for Wild type mice (Wt) and  DN-Trx1  (dominant negative for Trx1), whereas the 
Trx1 mice showed unchanged ADP/O values.  n=5 per group *p<0.05 vs. Nx, respectively. 
 
 


























































































































































































Figure 5.  Mitochondrial complexes activity. Panel A shows complex I activity. Panel A showed that 
the values of complex I activity in normoxic conditions (Nx) were increased in Trx1 mice compared 
with Wild type (Wt) and DN-Trx1 mice (dominant negative for Trx1), meanwhile 
ischemia/reperfusion process did not produce changes among the groups *p≤0.05 vs. Nx Trx1. 
Complex IV activities (panel B) were not modified by I/R in Wt (although slightly decreased) and 
Trx1 mice. However, DN-Trx1 group showed an inhibition after I/R process (Panel B).*p<0.05 vs. 
Nx DN-Trx1. Normoxic condition (Nx, n=4 per group); Ischemia/reperfusion (I/R, n=5).  
 


























































































































































































Figure 6: Mitochondrial Hydrogen peroxide (H2O2) production. The ischemia/reperfusion ( I/R) 
process increased H2O2  in Wild type mice (Wt, n= 5) and  DN-Trx1  (dominant negative for Trx1, 
n=6), whereas the Trx1 mice showed unchanged H2O2 values (n=6). * p<0.05 vs. normoxic (Nx, n=4 






































































































































































































Table 1: Left ventricle mitochondrial oxygen consumption supported by malate plus glutamate  
 
Mice Protocol 
Mitochondrial oxygen consumption 
(ng-at O/min.mg protein) 
  State 4 State3 RC 
Wild type Basal(0/0) 31 ±2 142±5 4.58 
 I/R(15/30) 32 ± 3 124±5 3.87 
Trx-1 Basal(0/0) 33±2 152±9 4.61 
 I/R(15/30) 40±3 154±6 †,‡ 3.85 
DN-Trx-1 Basal(0/0) 37±3 156±7 4.22 
 I/R(15/30) 36± 3 105±5 * 2.92 
 
Basal Wt (0/0) n = 7, Basal Trx-1 and DN-Trx-1 (0/0) n = 5, I/R (15/30) n =6. *DN-Trx-1 (15/30) vs. 




Table 2: Left ventricle mitochondrial oxygen consumption supported by malate-glutamate, in the 
presence of oligomycin or m-CCCP 
 
Mice Protocol 
Mitochondrial oxygen consumption 
(ng-at O/min.mg protein) 
  State 4o State 3u 3u/4o 
Wild type Basal(0/0) 34±2 139±9 4.09 
 I/R(15/30) 35±3 120±8 3.43 
























































































































































































Trx-1 Basal(0/0) 36±3 142±10 3.94 
 I/R(15/30) 45±4 147±6# 3.27 
DN-Trx-1 Basal(0/0) 38±2 143±10 3.76 




Nx Wt (0/0), n = 7;  Nx Trx-1 and DN-Trx-1 (0/0), n = 5;  I/R (15/30), n = 6 each group. * p<0.05 vs. 






(nmol/min mg protein) 
   
Wild type Basal (0/0) 63 ± 6 
 I/R (15/30) 70 ± 3 
   
   
Trx1 Basal (0/0) 67 ± 2 
 I/R (15/30) 69 ± 4 
   
   
DN-Trx1 Basal (0/0) 70 ± 4 




































































































































































































 (0/0):  normoxic conditions; 15/30: 15 min of ischemia and 30 min of reperfusion. n=5 per group. 
 
 I/R (15/30) 61 ± 3 
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ie
w
ed
 a
nd
 a
cc
ep
te
d 
fo
r 
pu
bl
ic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f 
co
rr
ec
tio
n.
 T
he
 f
in
al
 p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
if
fe
r 
fr
om
 th
is
 p
ro
of
.
